tiprankstipranks
Trending News
More News >

Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart

Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart

Confident Investing Starts Here:

Eledon Pharmaceuticals ( (ELDN) ) has provided an update.

Eledon Pharmaceuticals has announced promising initial results from a trial involving their investigational antibody, tegoprubart, in type 1 diabetes patients following islet transplantation. The first two participants achieved insulin independence, with enhanced islet engraftment and glucose control, compared to traditional tacrolimus-based treatments. These findings, presented at a major summit, highlight tegoprubart’s potential as a safer, effective alternative in managing transplant rejection and advancing diabetes treatment.

Learn more about ELDN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App